Nature5y
HYPERINSULINISM: A REVERSIBLE CAUSE OF HYPER-TROPHIC CARDIOMYOPATHY
We have recently cared for an infant with neonatal hypoglycemia secondary to endogenous organic, hyperinsulinism (blood glucose 22mg/dl; insulin 92uU/ml) that was refractory to diazoxide ...
Zacks.com on MSN16h
RZLT Shares Rise 30.8% in 6 Months: What's Driving the Rally?
Shares of Rezolute RZLT have rallied 30.8% in the past six months against the industry’s decline of 4.1%, driven by investor enthusiasm about the company’s encouraging progress with the development ...
Rezolute's ersodetug advances in pediatric study
REDWOOD CITY, Calif. - Rezolute , Inc. (NASDAQ:RZLT), a biopharmaceutical company with a market capitalization of $303.62 million and impressive recent momentum (up 13.91% in the past week), announced ...
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug ...
Rezolute provides update on Phase 3 sunRIZE study on ersodetug
Rezolute (RZLT) announced outcomes from an independent Data Monitoring Committee, DMC, review of the open label arm, OLA, portion of the ...
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism (HI) Ersodetug continues to advance in ...